The platform is also known to show much improved vaccine stability thus requiring lower cold chain requirements. This makes the vaccine ideal for access in remotest regions of the country. Administered through the intradermal route, it also allows for ease of administration. Further, the platform also provides ease of manufacturing the vaccine with minimal biosafety requirements (BSL-1). Furthermore, the platform can be rapidly used to modify the vaccine in a couple of weeks in case the virus mutates to ensure that the vaccine still elicits protection.

The plasmid DNA when introduced into the host cells would be translated into the viral protein and will elicit a strong immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, ICMR and NIV Pune in the development of ZyCoV-D.



Source link